<table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">interleukin-2-alzheimers-disease</th> </tr> <tr> <td class="label">Pathway</td> <td>Effect</td> </tr> <tr> <td class="label">Microglial suppression</td> <td>Tregs release IL-10, TGF-β → shift microglia from M1 to M2 phenotype</td> </tr> <tr> <td class="label">Cytokine reduction</td> <td>Decreased IL-1β, TNF-α, IL-6 in CNS parenchyma</td> </tr> <tr> <td class="label">Aβ clearance</td> <td>Improved microglial phagocytosis of amyloid plaques</td> </tr> <tr> <td class="label">Synapse protection</td> <td>Reduced complement-mediated synaptic pruning</td> </tr> <tr> <td class="label">Aspect</td> <td>Assessment</td> </tr> <tr> <td class="label">Novelty</td> <td>First-in-class immunomodulation approach for AD</td> </tr> <tr> <td class="label">Mechanism</td> <td>Addresses neuroinflammation as a core disease driver</td> </tr> <tr> <td class="label">Target population</td> <td>Early-to-moderate AD patients with biomarker evidence of inflammation</td> </tr> <tr> <td class="label">Combination potential</td> <td>Synergistic with anti-amyloid, anti-tau, or symptomatic therapies</td> </tr> <tr> <td class="label">Safety profile</td> <td>Known from oncology; low doses minimize risk</td> </tr> </table>
...
interleukin-2-alzheimers-disease
<table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">interleukin-2-alzheimers-disease</th> </tr> <tr> <td class="label">Pathway</td> <td>Effect</td> </tr> <tr> <td class="label">Microglial suppression</td> <td>Tregs release IL-10, TGF-β → shift microglia from M1 to M2 phenotype</td> </tr> <tr> <td class="label">Cytokine reduction</td> <td>Decreased IL-1β, TNF-α, IL-6 in CNS parenchyma</td> </tr> <tr> <td class="label">Aβ clearance</td> <td>Improved microglial phagocytosis of amyloid plaques</td> </tr> <tr> <td class="label">Synapse protection</td> <td>Reduced complement-mediated synaptic pruning</td> </tr> <tr> <td class="label">Aspect</td> <td>Assessment</td> </tr> <tr> <td class="label">Novelty</td> <td>First-in-class immunomodulation approach for AD</td> </tr> <tr> <td class="label">Mechanism</td> <td>Addresses neuroinflammation as a core disease driver</td> </tr> <tr> <td class="label">Target population</td> <td>Early-to-moderate AD patients with biomarker evidence of inflammation</td> </tr> <tr> <td class="label">Combination potential</td> <td>Synergistic with anti-amyloid, anti-tau, or symptomatic therapies</td> </tr> <tr> <td class="label">Safety profile</td> <td>Known from oncology; low doses minimize risk</td> </tr> </table>
warning: refname 'github/main' is ambiguous. title: Interleukin-2 Immunotherapy for Alzheimer's Disease description: IL-2 immunotherapy represents a novel approach to treating Alzheimer's disease by modulating regulatory T cell populations and reducing neuroinflammation. Phase II clinical trial (NCT06096090) is currently recruiting. published: true tags: kind:therapeutic, section:therapeutics, state:published editor: markdown dateCreated: "2026-03-29T12:30:00.000Z" dateUpdated: "2026-03-29T12:30:00.000Z" refs: grill2023: authors: Grill JD, et al title: Interleukin-2 and Alzheimer disease clinical trials journal: Neurology year: 2023 pmid: "37940556" dantoine2022: authors: Dantoine T, et al title: Low-dose IL-2 therapy in Alzheimer disease journal: J Prev Alzheimers Dis year: 2022 pmid: "36250660" yu2019: authors: Yu H, et al title: Regulatory T cells and neuroinflammation in Alzheimer disease journal: Nat Neurosci year: 2019 pmid: "31371802"
bfe67bb53c3c532ef4237fa3323691ae27404769
Interleukin-2 Immunotherapy for Alzheimer's Disease
Overview
Mermaid diagram (expand to render)
Interleukin-2 (IL-2) immunotherapy represents an emerging approach for [Alzheimer's disease](/diseases/alzheimers-disease) that targets the immune system rather than amyloid or tau directly. IL-2 is a cytokine that promotes the expansion and function of regulatory T cells (Tregs), which are key suppressors of neuroinflammation. A Phase II clinical trial (NCT06096090) is currently recruiting to evaluate the efficacy and safety of low-dose IL-2 in AD patients["@grill2023"].
The rationale stems from the observation that Tregs are reduced in number and function in AD patients, leading to unchecked microglial activation, chronic neuroinflammation, and accelerated neurodegeneration. Restoring Treg populations through IL-2 administration may suppress pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) and promote a more protective CNS environment["@yu2019"].
Mechanism of Action
IL-2 and Tregs
IL-2 is the primary cytokine driving Treg proliferation and survival:
Treg expansion: IL-2 binds the high-affinity IL-2 receptor (CD25/CD122/CD132) on Tregs, driving their clonal expansion
Mouse models: IL-2 administration in 5xFAD mice reduced amyloid burden, improved spatial memory, and increased Treg infiltration in the brain[@dantoine2022]
Human data: AD patients show reduced peripheral Tregs (~40% decrease vs. age-matched controls) and impaired Treg suppressive function
IL-2 in other diseases: Low-dose IL-2 is FDA-approved for melanoma and renal cell carcinoma; safe in elderly populations at low doses